Preclinical Evaluation of a Novel Triple-Acting PIM/PI3K/mTOR Inhibitor, IBL-302, in Breast Cancer

Oncogene - United Kingdom
doi 10.1038/s41388-020-1202-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines Under Normoxic and Hypoxic Conditions

Breast Cancer: Basic and Clinical Research
Cancer ResearchOncology
2014English

PIM-1 Kinase: A Potential Biomarker of Triple-Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Abrogating Phosphorylation of eIF4B Is Required for EGFR and mTOR Inhibitor Synergy in Triple-Negative Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2014English

A Novel PI3K Inhibitor PIK-C98 Displays Potent Preclinical Activity Against Multiple Myeloma

Oncotarget
Oncology
2014English

Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer

Oncogenesis
Cancer ResearchMolecular Biology
2017English

Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer

Journal of the American College of Surgeons
Surgery
2010English

Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Activity of Indatuximab Ravtansine Against Triple-Negative Breast Cancer in Preclinical Tumor Models

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2018English

Specific Apoptosis Induction by the Dual PI3K/mTor Inhibitor NVP-BEZ235 in HER2 Amplified and PIK3CA Mutant Breast Cancer Cells

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy